NO974513L - Pyrrolidinyl-hydroksamsyre-forbindelser og deres fremgangsmåte for fremstilling - Google Patents

Pyrrolidinyl-hydroksamsyre-forbindelser og deres fremgangsmåte for fremstilling

Info

Publication number
NO974513L
NO974513L NO974513A NO974513A NO974513L NO 974513 L NO974513 L NO 974513L NO 974513 A NO974513 A NO 974513A NO 974513 A NO974513 A NO 974513A NO 974513 L NO974513 L NO 974513L
Authority
NO
Norway
Prior art keywords
hydroxy
alkoxy
formula
hydroxamic acid
acid compounds
Prior art date
Application number
NO974513A
Other languages
English (en)
Other versions
NO974513D0 (no
Inventor
Fumitaka Ito
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO974513D0 publication Critical patent/NO974513D0/no
Publication of NO974513L publication Critical patent/NO974513L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Pyrrolidinyl-hydroksams}rc-forbindelscr og deres fremgangsmåte for fremstilling Forbindelse med formelen: Ar N. (D O N OR X og farmasøytisk godtagbare salter derav, hvor A er hydrogen, hydroksy eller OY, hvor Y er en hydroksy-beskyttelsesgruppe; Ar er fenyl eventuelt substituert med én eller flere substituenter valgt fra halogen, hydroksy, 0,-0^ alkyl, C,-C,alkoksy, GF3, C,-C4 alkoksy-C,-C, alkyloksy og karboksy-Ci-C^ alkyloksy; X er fenyl, naftyl, bifenyl, indanyl, benzofuranyl, benzotiofeny, 1-tetralon-6-yl, C,-C,, alkylendioksy, pyridyl, furyl og tienyl, idet disse grupper eventuelt er substituert med opptil tre substituenter valgt fra halogen, C,-C4 alkyl, 0,-0^ alkoksy, hydroksy, NO2, CF3 og SGjCHj; og R er hydrogen, 0,-0^ alkyl eller en hydroksy-beskyttelsesgruppe. Disse forbindelser og fanmasøytiske preparater inneholdende dem er nyttige som smertestillende, antiinflammatoriske, diuretiske, anestetiske eller nervebeskyttende midler eller som middel for behandling av slag eller funksjonelle tarm-sykdommer så som mavesmerte, for behandling av et pattedyr, spesielt et menneske. Foreliggende oppfinnelse tilveiebringer videre fremgangsmåter for fremstilling av hydroksamsyre-forbindelsene med formel (I) og mellomproduktene med formel (II).
NO974513A 1995-03-31 1997-09-29 Pyrrolidinyl-hydroksamsyre-forbindelser og deres fremgangsmåte for fremstilling NO974513L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9500631 1995-03-31
PCT/JP1996/000820 WO1996030339A1 (en) 1995-03-31 1996-03-28 Pyrrolidinyl hydroxamic acid compounds and their production process

Publications (2)

Publication Number Publication Date
NO974513D0 NO974513D0 (no) 1997-09-29
NO974513L true NO974513L (no) 1997-09-29

Family

ID=14125824

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974513A NO974513L (no) 1995-03-31 1997-09-29 Pyrrolidinyl-hydroksamsyre-forbindelser og deres fremgangsmåte for fremstilling

Country Status (35)

Country Link
US (2) US5952369A (no)
EP (1) EP0817772B1 (no)
JP (1) JP3035356B2 (no)
KR (1) KR100258657B1 (no)
AP (1) AP625A (no)
AR (1) AR002729A1 (no)
AT (1) ATE231840T1 (no)
AU (1) AU693336B2 (no)
BG (1) BG62611B1 (no)
BR (1) BR9607750A (no)
CA (1) CA2213815C (no)
CZ (1) CZ306497A3 (no)
DE (1) DE69626009T2 (no)
DK (1) DK0817772T3 (no)
ES (1) ES2188743T3 (no)
HR (1) HRP960141A2 (no)
HU (1) HUP9900767A3 (no)
IL (2) IL117440A0 (no)
IS (1) IS4547A (no)
LV (1) LV11971B (no)
MA (1) MA23832A1 (no)
NO (1) NO974513L (no)
NZ (1) NZ304113A (no)
OA (1) OA10518A (no)
PE (1) PE43397A1 (no)
PL (1) PL322652A1 (no)
RU (1) RU2144917C1 (no)
SI (1) SI9620039A (no)
SK (1) SK129897A3 (no)
TN (1) TNSN96045A1 (no)
TR (1) TR199701082T1 (no)
TW (1) TW408111B (no)
WO (1) WO1996030339A1 (no)
YU (1) YU18696A (no)
ZA (1) ZA962476B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9701042A (es) * 1996-02-07 1998-05-31 Pfizer Compuestos del acido hidroxamico.
TNSN97092A1 (ar) 1996-09-18 1999-12-31 Agouron Pharma مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
DE69720518T2 (de) * 1996-12-02 2004-02-26 Kyorin Pharmaceutical Co., Ltd. Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren
AU732430B2 (en) * 1997-01-10 2001-04-26 Merck & Co., Inc. Efficient synthesis of a chiral mediator
IL130429A0 (en) * 1998-08-24 2000-06-01 Pfizer Prod Inc Process for preparing pyrrolidinyl hydroxamic acid compounds
KR100295740B1 (ko) * 1998-09-17 2001-11-05 박영구 N-치환된-하이드록시고리화알킬아민유도체의제조방법
US6444829B1 (en) * 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
AU2002247886A1 (en) 2001-04-30 2002-11-11 Pfizer Products Inc. Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
AU2003269399A1 (en) * 2002-11-01 2004-05-25 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
GB0821010D0 (en) * 2008-11-17 2008-12-24 Univ Warwick Plant development control composition
JP6254075B2 (ja) 2011-05-16 2017-12-27 バイオノミックス リミテッド カリウムチャネル遮断剤としてのアミン誘導体
US9487510B2 (en) 2012-03-05 2016-11-08 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists
GB201210395D0 (en) * 2012-06-11 2012-07-25 Syngenta Participations Ag Crop enhancement compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3268539A (en) * 1963-05-20 1966-08-23 Universal Oil Prod Co Tertiary-aminoalkyl derivatives of diaryl substituted acetohydroxamic acid esters

Also Published As

Publication number Publication date
PE43397A1 (es) 1997-10-13
DE69626009D1 (de) 2003-03-06
BR9607750A (pt) 1998-06-30
EP0817772B1 (en) 2003-01-29
AU5121196A (en) 1996-10-16
NO974513D0 (no) 1997-09-29
WO1996030339A1 (en) 1996-10-03
HUP9900767A3 (en) 2001-01-29
US5952369A (en) 1999-09-14
CA2213815A1 (en) 1996-10-03
BG101896A (en) 1999-01-29
KR19980703476A (ko) 1998-11-05
CZ306497A3 (cs) 1998-07-15
DK0817772T3 (da) 2003-05-19
KR100258657B1 (ko) 2000-07-01
CA2213815C (en) 2001-12-18
TW408111B (en) 2000-10-11
AU693336B2 (en) 1998-06-25
HUP9900767A2 (hu) 1999-07-28
LV11971A (lv) 1998-02-20
IL117440A0 (en) 1996-07-23
US6110947A (en) 2000-08-29
RU2144917C1 (ru) 2000-01-27
ES2188743T3 (es) 2003-07-01
SI9620039A (sl) 1998-08-31
TNSN96045A1 (fr) 2005-03-15
AP625A (en) 1997-12-24
IS4547A (is) 1997-08-19
TR199701082T1 (xx) 1998-02-21
MX9707454A (es) 1998-07-31
BG62611B1 (bg) 2000-03-31
MA23832A1 (fr) 1996-10-01
OA10518A (en) 2002-04-22
NZ304113A (en) 1999-01-28
YU18696A (sh) 1999-06-15
JP3035356B2 (ja) 2000-04-24
HRP960141A2 (en) 1997-10-31
EP0817772A1 (en) 1998-01-14
PL322652A1 (en) 1998-02-16
AP9600791A0 (en) 1996-04-30
JPH11501048A (ja) 1999-01-26
AR002729A1 (es) 1998-04-29
ZA962476B (en) 1997-09-29
ATE231840T1 (de) 2003-02-15
DE69626009T2 (de) 2003-08-14
SK129897A3 (en) 1998-11-04
IL129479A0 (en) 2000-02-29
LV11971B (en) 1998-06-20

Similar Documents

Publication Publication Date Title
NO974513L (no) Pyrrolidinyl-hydroksamsyre-forbindelser og deres fremgangsmåte for fremstilling
CA2158108C (en) Compositions containing sertraline and a 5-ht1d receptor agonist or antagonist
NO20063382L (no) Nye kinolinderivater
JP3545416B2 (ja) フペルジンａ誘導体、その製造およびその使用
NO20060206L (no) Nye azetidinforbindelser
IS2503B (is) Ný efnasambönd
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
WO2006063113A3 (en) Ureas as factor xa inhibitors
AU2002336311B8 (en) Bicyclic compound
DE69514823T2 (de) Polyanionische benzyl-glykosiden als inhibitoren zur glatten-muskelzellen-proliferation
IT1230859B (it) 2 alchinilfenoli sostituiti ad azione anti infiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
PT746320E (pt) Intermediarios e inibidores da protease de hiv
ATE429429T1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
DE60324685D1 (de) 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
WO2008042755A2 (en) Inhibitors of cognitive decline
RU2001911C1 (ru) Способ получени замещенных 1,2,3,4-тетрагидронафталинов или их фармацевтически приемлемых аддитивных солей кислоты
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
DE69814473D1 (de) Neue allythiopyridazinderivate und verfahren zu ihrer herstellung
NO971687D0 (no) Diazepinoindoler som forsfodiesterase IV-inhibitorer
WO2008106125A3 (en) Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
ES8602734A1 (es) Un procedimiento para la preparacion de nuevos 5-hidroxi-2,3-dihidrobenzufuranos sustituidos y analagos.
IE60969B1 (en) Compounds with bronchodilator activity
EA200001101A1 (ru) НОВЫЕ ДИГИДРОФУРО[3,4-b]ХИНОЛИН-1-ОНЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
DE60307682D1 (de) Cyklisierungsverfahren für benzothiazolderivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application